Monoclonal Antibody Therapy in Sinonasal Disease

Chronic rhinosinusitis (CRS) affects 12.5% of the U.S.CRS can be divided into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps. Some individuals with CRSwNP do not respond to standard-of-care medical and surgical management. For these individuals, targeted biologic agents are emerging as an important therapeutic alternative. In this review, we described the most-relevant studies that addressed the use of anti-immunoglobulin E...